12:00 AM
 | 
May 11, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Daxas roflumilast regulatory update

Nycomed submitted an MAA to EMEA for Daxas roflumilast to treat chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis. Daxas is an oral phosphodiesterase-4 (PDE-4) inhibitor. Nycomed gained...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >